CUROSURF - CUROSURF - CT 4030 - English version

Has

Description

Introduction CUROSURF 120 mg/1.5 ml, suspension for intratracheal or intrabronchial use in a single-dose vial B/ 1 (CIP: 557 752-0) CUROSURF 240 mg/3 ml, suspension for intratracheal or intrabronchial use in a single-dose vial B/1 (CIP: 557 753-7) Posted on Apr 26 2010 Active substance (DCI) Phospholipid fraction from porcine lung ATC Code R07AA02 Laboratory / Manufacturer CHIESI SA CUROSURF 120 mg/1.5 ml, suspension for intratracheal or intrabronchial use in a single-dose vial B/ 1 (CIP: 557 752-0) CUROSURF 240 mg/3 ml, suspension for intratracheal or intrabronchial use in a single-dose vial B/1 (CIP: 557 753-7) Posted on Apr 26 2010

Sujets

• Médecine

Informations

• Publié par: haute-autorite-sante-traitement-medicamenteux
• Publié le: 28 février 2007
• Nombre de lectures: 52
• Licence : En savoir +
  Paternité, pas d'utilisation commerciale, partage des conditions initiales à l'identique
• Langue: English

Extrait

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 28 February 2007 CUROSURF 120 mg/1.5 ml, suspension for intratracheal or intrabronchial use in a single-dose vial B/ 1 (CIP: 557 752-0) CUROSURF 240 mg/3 ml, suspension for intratracheal or intrabronchial use in a single-dose vial B/1 (CIP: 557 753-7) Applicant : CHIESI SA Phospholipid fraction from porcine lung List I Medicinal product for hospital use only. For prescription in neonatal intensive care units only. Date of the Marketing Authorisation: August 6, 1992 Last revision (extension of indication): July 13, 2006 Reason for request: inclusion on the list of medicines approved for hospital use for the extension of indication: “treatment of premature neonates at high risk from respiratory distress syndrome (RDS) due to pulmonary surfactant deficiency (hyaline membrane disease).” Health Technology Assessment Division

1